Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating
Links shared publicly online about this topic.
- 1,109total visits
Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating
Salix Pharmaceuticals, Ltd. today announced that the Company has submitted an efficacy supplement to NDA 21-361 for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.
View full resource at news-medical.net
Tags: IBS, Disease and Condition, Supplement, Pharma
Most Recently Shared on June 8, 2010 at 2:11 pm By:
Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating: Salix Pharmaceuticals, L... http://bit.ly/ar1tUE
Advertisement
